A Comparison Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Congenital Factor VII Deficiency
Mohammad Faranoush(Iran University of Medical Sciences), Majid Naderi(Zahedan University of Medical Sciences), Ramin Heshmat(Tehran University of Medical Sciences), Azim Mehrvar(Army Medical University), N B Mirbehbahani(Golestan University), M R Baghaeipour(Hemophilia Center of Iran), Mehran Karimi(American University in Dubai), Hamid Hoorfar(Isfahan University of Medical Sciences), R. Fayazfar(Kerman University of Medical Sciences), B. Keikhaei Dehdezi(Ahvaz Jundishapur University of Medical Sciences), Peyman Eshghi(Shahid Beheshti University of Medical Sciences), B. khoeiny, Hassan Abolghasemi(Shahid Beheshti University of Medical Sciences), Kalantar-Zadeh Kamyar, Minoo Ahmadinejad(High Institute for Education and Research in Transfusion Medicine), Mohammad Reza Managhchi(Imam Khomeini Hospital), Gholamreza Toogeh(Imam Khomeini Hospital)
Cited by 17
Related Papers
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
|New England Journal of Medicine|2016|491
Overexpression of Orphan Receptor Tyrosine Kinase <i>Ror1</i> as a Putative Tumor-Associated Antigen in Iranian Patients with Acute Lymphoblastic Leukemia
|Tumor Biology|2007|46
Expression profile of orphan receptor tyrosine kinase (<i>ROR1</i>) and Wilms' tumor gene 1 (<i>WT1</i>) in different subsets of B-cell acute lymphoblastic leukemia
|Leukemia & lymphoma/Leukemia and lymphoma|2008|46
The Prognostic Value of Thrombocytopenia in COVID-19 Patients; a Systematic Review and Meta-Analysis.
|PubMed|2020|45
Inhibition of DNA-PK enhances chemosensitivity of B-cell precursor acute lymphoblastic leukemia cells to doxorubicin
|Biomedicine & Pharmacotherapy|2017|31